RT Journal Article
SR Electronic
T1 Outcome variables for osteoarthritis clinical trials: The OMERACT-OARSI set of responder criteria.
JF The Journal of Rheumatology
JO J Rheumatol
FD The Journal of Rheumatology
SP 1648
OP 1654
VO 30
IS 7
A1 Pham, Thao
A1 Van Der Heijde, Désirée
A1 Lassere, Marissa
A1 Altman, Roy D
A1 Anderson, Jennifer J
A1 Bellamy, Nicholas
A1 Hochberg, Marc
A1 Simon, Lee
A1 Strand, Vibeke
A1 Woodworth, Thasia
A1 Dougados, Maxime
A1 OMERACT-OARSI
YR 2003
UL http://www.jrheum.org/content/30/7/1648.abstract
AB Improvement in analysis and reporting results of osteoarthritis (OA) clinical trials has been recently obtained because of harmonization and standardization of the selection of outcome variables (OMERACT 3 and OARSI). Moreover, OARSI has recently proposed the OARSI responder criteria.This composite index permits presentation of results of symptom modifying clinical trials in OA based on individual patient responses (responder yes/no). The 2 organizations (OMERACT and OARSI) established a task force aimed at evaluating: (1) the variability of observed placebo and active treatment effects using the OARSI responder criteria; and (2) the possibility of proposing a simplified set of criteria. The conclusions of the task force were presented and discussed during the OMERACT 6 conference, where a simplified set of responder criteria (OMERACT-OARSI set of criteria) was proposed.